New drug aims to shrink HER2 breast tumors before surgery
NCT ID NCT07196774
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing a new drug called SHR-A1811 against a standard chemotherapy combination for women with early-stage or locally advanced HER2-positive breast cancer. About 740 participants will receive either the new drug or standard treatment before surgery. The main goal is to see if the new drug leads to a complete disappearance of cancer in the breast tissue removed during surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A1811 (an antibody-drug conjugate)
What this could lead to
If successful, SHR-A1811 could offer a more targeted, potentially less toxic neoadjuvant option for HER2-positive breast cancer, improving the chance of a complete response before surgery.
What could go wrong
This is a phase 3 trial, but results are not yet known. SHR-A1811 may not outperform the standard regimen, and side effects could be similar or different. Long-term benefits like survival are still being followed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shengjing Hospital, China Medical University
RECRUITINGShenyang, Liaoning, 110000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact